Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study
Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty tolerating standard chemotherapy regimens due to their comorbidities. Charlson Comorbidity Index (CCI), which is calculated by considering 19 different comorbidities, was developed in 1987 and is widely used for mortality prediction in cancer patients. Literature data on CCI and hematological malignancies are limited. Main aim in this study is to evaluate the effectiveness of CCI and compare to the International Prognostic Index (IPI) scoring system in the DLBCL patient group. Methods A total of 170 patients diagnosed with DLBCL between 1.1.2002- 1.12.2020 were included in the study. Statistical analyzes were performed among patients whose IPI and CCI scores were recorded by considering baseline data. Results The median age of patients was 58 (range: 17–84). Thirty-five (20.6%) patients had stage III and 76 (44.7%) had stage IV disease. When the CCI, IPI and ECOG scores were compared with the mortality status of the patients as a reference, AUCs were resulted as 0.628 (95% CI: 0.506–0.749), 0.563 (95% CI: 0.484–0.639) and 0.672 (95% CI: 0.596–0.743), respectively. There was no significant difference between the ROC curves of CCI, IPI and ECOG scores. Patients with a CCI score of ≥ 4 had shorter OS comperad to those with a score of < 4. Conclusion Rather than claiming that CCI is superior to IPI, ECOG or another scoring system in a single-center patient population, it should be stated that CCI is also an effective scoring system in patients diagnosed with DLBCL..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Indian journal of hematology and blood transfusion - 39(2022), 2 vom: 28. Sept., Seite 191-199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eren, Rafet [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Charlson Comorbidity Index |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12288-022-01567-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR04991166X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04991166X | ||
| 003 | DE-627 | ||
| 005 | 20230403083219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230403s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12288-022-01567-5 |2 doi | |
| 035 | |a (DE-627)SPR04991166X | ||
| 035 | |a (SPR)s12288-022-01567-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eren, Rafet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Indian Society of Hematology and Blood Transfusion 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of adult lymphomas. The incidence of DLBCL increases with age and has a fairly rapid fatal course without treatment. Patients often have difficulty tolerating standard chemotherapy regimens due to their comorbidities. Charlson Comorbidity Index (CCI), which is calculated by considering 19 different comorbidities, was developed in 1987 and is widely used for mortality prediction in cancer patients. Literature data on CCI and hematological malignancies are limited. Main aim in this study is to evaluate the effectiveness of CCI and compare to the International Prognostic Index (IPI) scoring system in the DLBCL patient group. Methods A total of 170 patients diagnosed with DLBCL between 1.1.2002- 1.12.2020 were included in the study. Statistical analyzes were performed among patients whose IPI and CCI scores were recorded by considering baseline data. Results The median age of patients was 58 (range: 17–84). Thirty-five (20.6%) patients had stage III and 76 (44.7%) had stage IV disease. When the CCI, IPI and ECOG scores were compared with the mortality status of the patients as a reference, AUCs were resulted as 0.628 (95% CI: 0.506–0.749), 0.563 (95% CI: 0.484–0.639) and 0.672 (95% CI: 0.596–0.743), respectively. There was no significant difference between the ROC curves of CCI, IPI and ECOG scores. Patients with a CCI score of ≥ 4 had shorter OS comperad to those with a score of < 4. Conclusion Rather than claiming that CCI is superior to IPI, ECOG or another scoring system in a single-center patient population, it should be stated that CCI is also an effective scoring system in patients diagnosed with DLBCL. | ||
| 650 | 4 | |a Diffuse large B-cell lymphoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Charlson Comorbidity Index |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a prognosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a efficacy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Serin, Istemi |0 (orcid)0000-0003-1855-774X |4 aut | |
| 700 | 1 | |a Atak, Suheyla |4 aut | |
| 700 | 1 | |a Pirdal, Betul Zehra |4 aut | |
| 700 | 1 | |a Nizam, Nihan |4 aut | |
| 700 | 1 | |a Gemici, Aliihsan |4 aut | |
| 700 | 1 | |a Aydın, Demet |4 aut | |
| 700 | 1 | |a Demirel, Naciye |4 aut | |
| 700 | 1 | |a Dogan, Esma Evrim |4 aut | |
| 700 | 1 | |a Yokus, Osman |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of hematology and blood transfusion |d Neu Delhi : Springer India, 2007 |g 39(2022), 2 vom: 28. Sept., Seite 191-199 |w (DE-627)SPR024793558 |w (DE-600)2422370-0 |x 0974-0449 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:2 |g day:28 |g month:09 |g pages:191-199 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12288-022-01567-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 2 |b 28 |c 09 |h 191-199 | ||